HLA-B*14:02 and HLA*B-40:02 are enriched in patients with aAA compared with race-matched control patients
| Population . | Individuals, n . | HLA-B*14:02 . | HLA-B*40:02 . | ||||
|---|---|---|---|---|---|---|---|
| Present, n (%) . | Absent, n (%) . | P . | Present, n (%) . | Absent, n (%) . | P . | ||
| USA NMDP European Caucasian | 1 242 890 | 71 093 (5.7) | 1 171 797 (94.3) | 31 321 (2.5) | 1 211 569 (97.5) | ||
| Aplastic anemia, white | 42 | 12 (28.6) | 30 (71.4) | .000 | 4 (9.5) | 38 (90.5) | .021 |
| MDS, white | 163 | 13 (8.0) | 150 (92.0) | .233 | 4 (2.5) | 159 (97.5) | 1.000 |
| Population . | Individuals, n . | HLA-B*14:02 . | HLA-B*40:02 . | ||||
|---|---|---|---|---|---|---|---|
| Present, n (%) . | Absent, n (%) . | P . | Present, n (%) . | Absent, n (%) . | P . | ||
| USA NMDP European Caucasian | 1 242 890 | 71 093 (5.7) | 1 171 797 (94.3) | 31 321 (2.5) | 1 211 569 (97.5) | ||
| Aplastic anemia, white | 42 | 12 (28.6) | 30 (71.4) | .000 | 4 (9.5) | 38 (90.5) | .021 |
| MDS, white | 163 | 13 (8.0) | 150 (92.0) | .233 | 4 (2.5) | 159 (97.5) | 1.000 |
USA NMDP, US National Marrow Donor Program.
P values refer to comparisons between patients with aAA or MDS, as compared with the race-matched USA NMDP European Caucasian control population. Statistically significant P values are shown in bold.